Document is current
Any future updates will be listed below
-
Authors
Koper, Marta J.
Tomé, Sandra O. http://orcid.org/0000-0001-5253-0730
Gawor, Klara
Belet, Annelies
Van Schoor, Evelien
Schaeverbeke, Jolien
Vandenberghe, Rik
Vandenbulcke, Mathieu
Ghebremedhin, Estifanos
Otto, Markus
von Arnim, Christine A. F.
Balusu, Sriram
Blaschko, Matthew B.
De Strooper, Bart
Thal, Dietmar Rudolf http://orcid.org/0000-0002-1036-1075
-
Funding
Funding for this research was provided by:
Alzheimer Forschung Initiative (13803)
Fonds Wetenschappelijk Onderzoek (G065721N, G0F8516N, 1S46219N, 12Y1620N)
Vlaamse Impulsfinanciering voor Netwerken voor Dementie-onderzoek (IWT 135043, IWT 135043)
Onderzoeksraad, KU Leuven (PDMT2/21/069)
Stichting Alzheimer Onderzoek (SAO-FRA 2021/00022)
- License Information
-
More Information
Article History
Received: 15 August 2022
Accepted: 15 August 2022
First Online: 3 September 2022
Declarations
:
: All autopsies were carried out according to local legislation with appropriate consent. Ethical approval for the use of cases was granted by the ethical committee of Ulm University (Germany) and UZ/KU-Leuven ethical committee (Belgium). This study covering the retrospective analysis of samples and data was approved by the UZ/KU-Leuven ethical committee (S-59295, S-65147) (Belgium).
: Not applicable for this study, which did not use person’s data. Only anonymized or pseudonymized data were processed.
: MO served as consultant for Axon neuroscience and Fujirebio and gave invited talks for Roche and Fujirebio. CAFvA received honoraria from serving on the scientific advisory board of Nutricia GmbH (2014), Roche (2018) and Hong Kong University Research council (2014) and has received funding for travel and speaker honoraria from Nutricia GmbH (2014–2015), Lilly Deutschland GmbH (2013–2016), Desitin Arzneimittel GmbH (2014), Biogen (2016–2018), Roche (2017–2019) and Dr. Willmar Schwabe GmbH &Co. KG (2014–2019). BDS is or has been a consultant for Eli Lilly, Biogen, Janssen Pharmaceutica, Eisai, AbbVie and other companies. BDS is also a scientific founder of Augustine Therapeutics and a scientific founder and stockholder of Muna therapeutics. DRT received speaker honorary from Novartis Pharma AG (Switzerland) and Biogen (USA), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).
